Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australian Biotech CSL Sees Talecris Acquisition As Ticket To Grow Plasma Therapeutics

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - In what is being called the biggest Australian biotech acquisition, Melbourne-based CSL Limited inked a deal to acquire Talecris Biotherapeutics for $3.1 billion, CSL announced Aug. 13

You may also be interested in...



U.S. FTC Blocks Australian CSL’s Acquisition of Talecris, Noting Consolidation Would Reduce Competition

PERTH, Australia - The U.S. Federal Trade Commission has authorized a lawsuit to stop Australian-based CSL Limited's $3.1 billion acquisition of Talecris Biotherapeutics, charging that the deal "would be illegal and would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies," the commission announced May 27

U.S. FTC Blocks Australian CSL’s Acquisition of Talecris, Noting Consolidation Would Reduce Competition

PERTH, Australia - The U.S. Federal Trade Commission has authorized a lawsuit to stop Australian-based CSL Limited's $3.1 billion acquisition of Talecris Biotherapeutics, charging that the deal "would be illegal and would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies," the commission announced May 27

New Zealand’s PHARMAC Funds J&J’s Concerta, Topamax: Australia/New Zealand Regulatory Roundup

PERTH, Australia - New Zealand's Pharmaceutical Management Agency will now fund Johnson & Johnson's Concerta (methylphenidate extended release) for the treatment of attention deficit hyperactivity disorder, beginning Sept. 1

Related Content

UsernamePublicRestriction

Register

SC069291

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel